🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Alpha Teknova, Inc. TKNO R2K

Healthcare · Drug Manufacturers - Specialty & Generic · United States
https://www.teknova.com

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

READ MORE ›
$5.40
-6.41% 1Y

Market & Price

Market Cap
$289.52M
Current Price
$5.40
High / Low (52W)
$6.37 / $1.99
Beta
0.47

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$1.28
Price to Book
4.21
P/S
6.93
EV/EBITDA
-31.63
Dividend Yield
-

Profitability & Returns

ROCE
-17.17%
ROE
-23.92%
ROA
-9.29%
Profit Margin
-41.07%
Op Margin
-38.80%
EPS (Latest Qtr)
$-0.08
EPS (TTM)
$-0.31

Balance Sheet & Liquidity

Debt/Equity
0.43
Quick Ratio
3.40
Current Ratio
4.59
Debt
$27.83M
Total Assets
$103.58M
Current Assets
$34.51M
Working Capital
$26.97M

Ownership

Promoter Holding
9.32%
Chg in Prom Hold
-
FII / Inst Holding
84.72%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$299.56M
Total Revenue (TTM)
$41.80M
EBITDA
$-9.47M
Free Cash Flow
$-2.39M
Operating Cash Flow
$-7.90M
Shares Outstanding
53.61M
Gross Margin
34.01%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
-0.73%
Profit 5Y
21.21%
Revenue (YoY)
13.10%
Earnings (YoY)
-

PROS

  • Profit CAGR of 21.2% over 5 years.

CONS

  • Revenue declined at -0.7% CAGR over 5 years.
  • In a downtrend (50-DMA below 200-DMA).
  • RSI at 81 suggests overbought conditions.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 TKNO Alpha Teknova, Inc. R2K 5.40 - $289.52M - -17.17% -23.92% -0.73% 21.21%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 6.04M8.98M9.08M8.31M9.39M11.15M11.69M10.69M9.12M11.53M8.17M9.29M9.61M--9.79M10.29M10.45M9.98M11.08M
Cost of Revenue ---------------6.79M6.30M7.25M6.74M7.29M
Gross Profit 3.47M5.09M5.03M3.35M4.26M5.35M5.25M4.77M2.42M5.07M1.47M2.21M2.80M--3.01M3.98M3.21M3.24M3.78M
Operating Expenses ---------------7.97M7.37M7.22M7.85M8.08M
Operating Income 704.00K2.15M-828.00K-2.53M-3.89M-5.84M-6.63M-22.95M-8.95M-7.00M-8.76M-7.99M-5.10M---4.96M-3.39M-4.02M-4.61M-4.30M
EBITDA ----------------2.90M-1.80M-2.43M-3.03M-2.71M
Interest Expense ---------------144.00K165.00K190.00K211.00K219.00K
Pretax Income ----------------4.62M-3.55M-4.21M-4.82M-4.51M
Tax Provision ---------------22.00K19.00K79.00K-62.00K47.00K
Net Income 512.00K1.53M-655.00K-2.25M-3.25M-5.50M-6.20M-22.47M-8.82M-7.15M-10.15M-8.10M-5.36M---4.64M-3.57M-4.29M-4.76M-4.55M
Diluted EPS 0.020.07--0.52-0.12-0.20-0.22-0.80-0.31-0.25-0.34-0.20-0.13---0.09-0.07-0.08-0.09-0.08
R&D Expense 341.00K358.00K700.00K851.00K1.37M2.01M1.93M1.93M1.40M1.46M1.40M860.00K678.00K627.00K-552.00K581.00K542.00K-609.00K

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 31.30M-41.42M36.68M37.74M40.52M
Cost of Revenue --23.94M26.39M30.51M27.08M
Gross Profit 17.75M-17.48M10.30M7.23M13.44M
Operating Expenses --46.33M41.49M33.38M30.42M
Operating Income 4.66M--28.86M-31.20M-26.15M-16.98M
EBITDA ---25.69M-30.59M-19.57M-10.15M
Interest Expense ---833.00K687.00K710.00K
Pretax Income ---49.39M-37.08M-26.83M-17.20M
Tax Provision ---1.92M-298.00K-88.00K58.00K
Net Income 3.57M--47.47M-36.78M-26.75M-17.26M
Diluted EPS 0.16--1.69-1.16-0.57-0.32
R&D Expense 1.51M4.31M7.74M5.57M2.76M2.20M

Compounded Sales Growth

5 Years:-0.73%
1 Year:13.10%

Compounded Profit Growth

5 Years:21.21%
1 Year:-

Stock Price Performance

1 Year:-6.41%
6 Months:+16.13%
3 Months:+109.30%
1 Month:+67.18%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -62.91M-152.26M128.59M118.77M103.58M
Current Assets ---61.14M45.66M42.78M34.51M
Cash & Equivalents 4.14M3.31M-42.24M28.48M3.71M5.91M
Inventory ---12.25M11.59M6.80M7.05M
Receivables ---4.26M3.95M4.31M4.62M
Total Liabilities -10.51M-52.38M38.55M36.38M34.81M
Current Liabilities -3.96M-10.88M8.88M11.21M7.54M
Long Term Debt -0-21.98M13.25M9.44M13.12M
Total Debt ---42.31M30.46M30.17M28.27M
Total Equity 12.91M16.77M-99.89M90.04M82.39M68.78M
Shares Outstanding ---28.18M40.79M53.41M53.56M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 2.50M--27.40M-18.81M-12.39M-8.65M
Investing Cash Flow -1.74M--28.15M-7.74M-27.27M10.70M
Financing Cash Flow -1.60M-10.27M12.80M14.89M151.00K
Capital Expenditure -5.47M--28.15M-7.93M-1.12M-1.15M
Free Cash Flow -2.96M--55.55M-26.75M-13.52M-9.79M
Net Change in Cash ---45.28M-13.75M-24.78M2.20M

Ratios (Annual)

Figures in %.

Metric Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 56.7%-42.2%28.1%19.2%33.2%
Operating Margin % 14.9%--69.7%-85.0%-69.3%-41.9%
Net Margin % 11.4%--114.6%-100.3%-70.9%-42.6%
ROE % 21.3%--47.5%-40.9%-32.5%-25.1%
ROCE % 7.9%--20.4%-26.1%-24.3%-17.7%

Shareholding Pattern

Insiders
9.32%
Institutions
84.72%
Public Float
93.43%

Top Institutional Holders

#Holder% HeldSharesValue
1 Roubaix Capital, LLC 3.51% 1.88M $10.16M
2 Royce & Associates LP 1.99% 1.07M $5.77M
3 Blackrock Inc. 1.34% 716.77K $3.87M
4 Millennium Management Llc 0.83% 447.14K $2.41M
5 Vanguard Capital Management LLC 0.82% 441.88K $2.39M
6 UBS Group AG 0.61% 325.16K $1.76M
7 Conestoga Capital Advisors, LLC 0.59% 317.08K $1.71M
8 Geode Capital Management, LLC 0.57% 307.87K $1.66M
9 Bank of America Corporation 0.43% 228.29K $1.23M
10 Massar Capital Management, LP 0.37% 200.00K $1.08M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TKNO

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks